Price Increases of Protected-Class Drugs in Medicare Part D, Relative to Inflation, 2012-2017.
retrospective_cohort · Level III
Where this comes from
- Record sourced from PubMed, PMID 31310287.
- Also identified by DOI 10.1001/jama.2019.7521 and PMC identifier 6635901.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
This study characterizes price increases exceeding inflation between 2012 and 2017 for protected-class drugs (antineoplastics, antiretrovirals, antidepressants, antipsychotics, anticonvulsants, and immunosuppressants for transplant patients) that would lead to their exclusion from Medicare Part D coverage based on excessive cost under a 2018 CMS rule intended to facilitate more effective price negotiations.
Medical subject headings
- Drug Costs
- Inflation, Economic
- Medicare Part D
- Prescription Drugs